Interferon Beta Drugs Market: Is 2026 the Year Biosimilar...

σε πρόσθεσε στο Health

2026-02-12 06:05:24 -

Interferon Beta Drugs Market: Is 2026 the Year Biosimilar Competition Finally Breaks the MS Pricing Barrier?

In early 2026, the Interferon Beta Drugs Market is valued at $10.54 billion, representing a critical turning point for Multiple Sclerosis (MS) therapy. This year, the industry is witnessing the "Biosimilar Reset," as patents for several blockbuster originators expire, paving the way for more affordable non-originator biologicals like BCD-033. This innovation is a primary driver for the market,...

0 Σχόλια 0 Μοιράστηκε 18 Views 0 Προεπισκόπηση